No Data
No Data
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
No Data
Ultratech :